The interference with deep venous blood flow may be brought about by inexpert bandaging. The importance of a meticulous and practical bandaging technique has recently been re-emphasized (Fegan, 1971).

In addition, many patients feel that a bandaged limb should be 'rested'. Inactivity of the calf muscle pumps appreciably slows the rate of deep venous return. We give detailed instructions to our patients about increasing their activities, especially walking, during the period of treatment. We have not previously insisted that they walk 2 to 3 miles immediately following treatment, as do some clinics (Fegan, 1967). Nevertheless, it may be significant that in this case, almost immediately following treatment, the patient had a long car journey to return home. This subsequent inactivity would appear to have appreciably increased the risk of deep venous thrombosis.


**Case reports**

**Pulmonary reaction to Furoxone**

**J. V. Collins**
M.B., M.R.C.P.

**A. L. Thomas**
M.B., M.R.C.P.

**Guy's Hospital, London, S.E.1**

**Summary**

A patient is reported in whom an acute pulmonary reaction resulted from the ingestion of Furoxone (furazolidine), a member of the nitrofurantoin group of drugs. A positive lymphocyte transformation test to Furoxone was found. This is thought to suggest that Type IV (Gell & Coombs, 1968) thymus dependent hypersensitivity may be implicated in such pulmonary reactions.

When a patient develops what is suspected to be a hypersensitivity reaction to a drug, the problem of identifying the drug responsible becomes more difficult as the number and variety of drugs available for prescription increases. It has been shown that between 5–10% of patients admitted to hospital experience some toxic or hypersensitivity reaction to a drug (Reeves & Trounce, 1971). Antibiotics, hypnotics and tranquillizers are the drugs most likely to produce such reactions (MacDonald & Mackay, 1964). We report a patient in whom a respiratory illness complicated drug therapy for an unrelated condition.

**References**


**Case history**

The patient, K.P., a man aged 56 years, was admitted to St Olave's Hospital on 23 March 1971 with a 12-day history of fever, rigors, generalized rash and night sweats associated with general malaise. From September 1970, he had been complaining of severe low back pain, which after extensive investigation was found to be due to osteomyelitis of L3/4. This was treated with a 5-week course of cloxacillin (3-chlorophenyl-5-methyl-4-isoxazolyl penicillin) until 11 February 1971. His back pain improved and his ESR fell. He travelled to Tangier for a convalescent holiday and 5 days later he developed nausea and anorexia after meals, without vomiting or diarrhoea. He returned to England on 28 February 1971, and because of persistence of these symptoms he suspected that he had a gastro-intestinal infection and treated himself with Furoxone (3-(5-nitrofururylideneamino)-2-oxo-oxazolidine) for 5 days, finishing on 9 March 1971. 2 days later he became febrile with rigors and breathlessness. His back pain returned and on 11 March 1971 he took 500 mg of ampicillin (a-amino benzyl penicillin). The following day he had a generalized urticarial scarlatiniform rash. He changed immediately to Floxapen (flucoxa-
cillin) 500 mg t.d.s., which he took for 11 days, the rash fading on the second day.

He was admitted to hospital on 17 May 1971 and on examination he was pyrexial, breathless on slight exertion and the only abnormal physical signs were splinter haemorrhages under the right thumb nail and tenderness over the 4th lumbar vertebra. Chest X-ray on admission showed diffuse mottling throughout both lung fields (Fig. 1) which cleared 7 days later (Fig. 2).

**Laboratory investigations** on admission to hospital included:

- Haemoglobin = 14.9 g/100 ml, white blood count = 17,500/mm³, eosinophils = 1050/mm³ (6%), ESR = 22 mm/hr. Plasma proteins; total—7.0 g/100 ml, albumin = 3.7 g/100 ml. Electrophoresis normal.
- Staph.-anti-streptolysin titre 1 unit (normal 0–2).
- Electrolytes normal. Blood urea = 38 mg/100 ml.
- MSU, sterile.
- Sputum for AFB and malignant cells, negative.
- Rose Waaler and Latex fixation, both negative. Agglutination tests for Brucella, *Salmonella typhi*, *S. paratyphi* A and B, negative. No pathogens isolated from stools. Bone marrow, normal. Kveim test, negative. Lymphocyte transformation test was carried out by Dr S. Alexander, using the method incorporating 14C thymidine, described in detail elsewhere (Forman & Alexander, 1972). The results showed a strongly positive reaction to Furoxone.

**Respiratory function tests** were not available until after recovery, but then showed:

<table>
<thead>
<tr>
<th>Test</th>
<th>Predicted</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1 (litres)</td>
<td>3.0</td>
</tr>
<tr>
<td>FVC (litres)</td>
<td>3.5</td>
</tr>
<tr>
<td>PEFR (l/min)</td>
<td>600</td>
</tr>
<tr>
<td>FER</td>
<td>86%</td>
</tr>
</tbody>
</table>

Carbon monoxide transfer factor: TLCO = 22 ml/min mmHg (predicted value, 29 ml/min/mmHg).

**Discussion**

It is known that Furadantin (1-(5-nitrofururylideneamino-hydantoin) may produce a toxic megaloblastic anaemia and pulmonary infiltration due to a hypersensitivity reaction. In the acute form of pulmonary reaction, cough, dyspnoea and fever often accompanied by myalgia and a maculo-papular rash may occur. Diffuse pulmonary shadows are seen on chest X-ray. Leukocytosis and eosinophilia may occur. After withdrawal of the drug, the condition quickly resolves, but a chronic form with insidious onset unassociated with fever may proceed to pulmonary fibrosis (British Medical Journal, 1969; Rosenow et al., 1968). The immunological basis for these reactions is thought to be a Type III reaction of Gell & Coombs (Gell & Coombs, 1968).

Furoxone (3-(5-nitrofururylideneamino)-2-oxo-oxazolidine) is an antibacterial agent of similar chemical structure to Furadantin, and it is known to cause maculo-papular, vesicular and urticarial skin eruptions (Kautz, 1960). It has been noted that the ingestion of alcohol in patients who are receiving the drug can bring about excessive skin flushing and dyspnoea similar to the reaction manifested by giving Antabuse (Kautz, 1960). No pulmonary effects have
yet been recorded. The patient we reported presented with a febrile illness, breathlessness, urticaria and eosinophilia associated with diffuse pulmonary infiltration on chest X-ray. From these findings we suspected a drug reaction. Furoxone is likely to have been the cause, as the related drug Furadantin is known to cause pulmonary reactions. The rash disappeared while the patient was receiving Floxapen, which suggests that ampicillin can probably be excluded as the cause of the rash, for patients sensitized to one member of the penicillin group often show sensitivity to the others.

It is probable that this pulmonary reaction is of Type III, in which immune complexes are present in the bloodstream, represented by the Arthus phenomenon and serum sickness. The antibodies involved may be of the IgG and IgM classes. An arteritis is thought to be responsible for the fine mottling on X-ray which accompanies this type of reaction (Davies, 1969). Few specific tests are at present available for typing hypersensitivity reactions, the lymphocyte transformation test used in our patient is usually taken as an in vitro measure of a potential in vivo delayed hypersensitivity response, Type IV hypersensitivity (Gell & Coombs, 1968; Sarkany, 1967). Our findings of a positive lymphocyte transformation may perhaps indicate that the mechanisms underlying infiltration due to drugs of the Furadantin group may involve both Type III and IV reactions.

Acknowledgments
We should like to thank Dr K. S. MacLean for permission to publish this case report and Dr S. Alexander for carrying out the lymphocyte transformation studies.

References
Pulmonary reaction to furoxone

J. V. Collins and A. L. Thomas

doi: 10.1136/pgmj.49.573.518

Updated information and services can be found at:
http://pmj.bmj.com/content/49/573/518

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/